[Drug prevention of bronchial asthma: inhibition of histamine and exercise-induced asthma by a new anti-anaphylactic oral preparation (ketotifen) (author's transl)].
The protective anti-asthmatic effect of a new anti-allergic drug with histaminolytic and anti-anaphylactic properties was tested in various controlled clinical studies of induced bronchospasm in asthmatic patients (provocation tests using a histamine aerosol, and exercise-induced asthma using a bicycle ergometer). The drug, ketotifen (a cycloheptathiophene derivative) was compared with a classical antihistaminic (clemastine) and a known cell stabiliser (disodium cromoglycate). In both models ketotifen provided significant protection.
D000328:Adult; D001249:Asthma / Q000517:prevention & control*; D001986:Bronchial Spasm / Q000517:prevention & control; D002974:Clemastine / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000627:therapeutic use; D006632:Histamine; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D005082:Physical Exertion; D010880:Piperidines / Q000627:therapeutic use*; D013147:Spirometry; D013876:Thiophenes / Q000627:therapeutic use*
D006634:Histamine H1 Antagonists; D010880:Piperidines; D013876:Thiophenes; D006632:Histamine; D002974:Clemastine; D004205:Cromolyn Sodium
Zur medikamentösen Bronchialasthma-Prophylaxe. Inhibitorischer Effekt einer neuen oral wirksamen antianaphylaktischen Substanz (Ketotifen) auf den histamin- und anstrengungs-induzierten Bronchospasmus.